Aclaris Therapeutics(NASDAQ) ACRS

Market Cap$947.96M

Since IPO (2015)-42%

5 Year-53%

1 Year+260%

1 Month+16%

$6.41

+1.67%

+0.10Today

After hours$6.44+$0.02 (+0.39%)

Aclaris Therapeutics last closing stock price
Metric	Price	Date
Last close	USD 6.44	2026-08-19

Aclaris Therapeutics stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+10.27%	USD 5.84	2026-08-12
1 month	+15.62%	USD 5.57	2026-07-20
3 month	+41.85%	USD 4.54	2026-05-21
Year to date	+113.95%	USD 3.01	2025-12-31
1 year	+259.78%	USD 1.79	2025-08-19
3 year	-9.93%	USD 7.15	2023-08-18
5 year	-53.27%	USD 13.78	2021-08-20
Since inception	-41.72%	USD 11.05	2015-10-07

Aclaris Therapeutics Financials at a Glance

Market Cap

$947.96M

Revenue (TTM)

$8.22M

Net Income (TTM)

-$75.74M

EPS (TTM)

-$0.59

P/E Ratio

-11.01

Dividend

$0.00

Beta (Volatility)

1.11 (Average)

Dividend

$0.00

Beta (Volatility)

1.11 (Average)

Price

$6.41

Volume

202.005

Open

$6.40

Price

$6.41

Volume

202.005

Open

$6.40

Previous Close

$6.44

Daily Range

$6.20 - $6.45

52-Week Range

$1.74 - $6.52

Estimated Earnings Date

Nov 5, 2026

Dividend

$0.00

Beta (Volatility)

1.11 (Average)

Price

$6.41

Volume

202.005

Open

$6.40

Previous Close

$6.44

Daily Range

$6.20 - $6.45

52-Week Range

$1.74 - $6.52

Estimated Earnings Date

Nov 5, 2026

ACRS News

Two people seated at a lab desk featuring a PC screen and microscope

ACRS: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Aclaris Therapeutics

Aclaris makes medicines for painful skin and lung conditions. It builds drugs that stop swelling and immune irritation. These treatments help patients who lack other good options.

The Pipeline at a Glance

Biologic Medicines: Advanced treatments like bosakitug that use proteins called antibodies to block specific signals causing skin and lung inflammation.
Small Molecule Drugs: Pill-based treatments like ATI-2138 designed to stop specific enzymes from triggering immune system responses in the body.
Laboratory Services: Contract research segment that provides specialized testing and lab work for other pharmaceutical companies.

Strategic Moves and Partnerships

Licensed global rights for the medicines bosakitug and ATI-052 from Biosion in November 2024 to expand the product pipeline.
Collaborated with CTTQ and Biosion to develop immune-focused treatments in specific global regions.
Acquired Confluence in 2017 to gain access to proprietary technology for building drugs that block inflammatory enzymes.
Granted rights to develop and sell the drug lepzacitinib in Greater China to Pediatrix Therapeutics in 2022.

How Aclaris Finds New Drugs

The company uses its own KINect platform to build drugs that target the kinome, a large family of genes that control cell signals. This technology helps create highly specific medicines that aim to reach diseased tissue while reducing unwanted side effects in the rest of the body.

The Latest Financial Numbers

Revenue was $1.3 million in Q4 2025, down 85.9% from $9.2 million in Q4 2024.
Operating income was a loss of $22.7 million in Q4 2025, narrowing from a $99.7 million loss in Q4 2024.
Net income reached a loss of $19.8 million in Q4 2025, an improvement from a $96.6 million loss in the previous year.
Free cash flow reached negative $13.1 million in Q4 2025, up from negative $44.7 million in Q4 2024.
Market capitalization reached $369 million in Q4 2025, up 56.2% from $236 million in Q4 2024.

Bottom Line

Aclaris has shifted from a broad skin-care focus to a specialized developer of biologic and pill-based drugs for the immune system. Its growth depends on turning its discovery technology into approved treatments through clinical trials and global partnerships.

AI Generated • May 5, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

Neal S. Walker, PhD, MBA

Website

www.aclaristx.com

Headquarters

Wayne, PA 19087, US

ACRS Financials

Key Financial Metrics (TTM)

Gross Margin

95.61%

Operating Margin

-1050.16%

Net Income Margin

-921.50%

Return on Equity

-61.65%

Return on Capital

-72.60%

Return on Assets

-42.15%

Earnings Yield

-9.08%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$947.96M

Shares Outstanding

147.20M

Volume

202.005

Avg. Volume

1.78M

Financials (TTM)

Gross Profit

$7.86M

Operating Income

-$86.31M

EBITDA

-$75.12M

Operating Cash Flow

-$62.06M

Capital Expenditure

-$118.00K

Free Cash Flow

-$62.18M

Cash & ST Invst.

$91.56M

Total Debt

$0.00

Aclaris Therapeutics Performance Analysis

Aclaris Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 29,752,000	340.1%
2023	2023-12-31	USD 31,249,000	5.0%
2024	2024-12-31	USD 18,720,000	-40.1%
2025	2025-12-31	USD 7,826,000	-58.2%

Aclaris Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	85.6%
Q4	2025-12-31	-60.7%
Q1	2026-03-31	54.1%
Q2	2026-06-30	-18.4%

Aclaris Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -1.33	-16.8%
2023	2023-12-31	USD -1.27	-4.9%
2024	2024-12-31	USD -1.71	34.8%
2025	2025-12-31	USD -0.53	-69.0%

Aclaris Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	7.7%
Q4	2025-12-31	-33.3%
Q1	2026-03-31	6.3%
Q2	2026-06-30	N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$1.63M

-8.3%

Gross Profit

$1.40M

+2015.1%

Gross Margin

85.82%

N/A

Market Cap

$947.96M

N/A

Market Cap/Employee

$13.35M

N/A

Employees

N/A

Net Income

-$21.51M

-39.4%

EBITDA

-$21.30M

-26.8%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$91.56M

-8.3%

Total Debt

$0.00

-100.0%

Accounts Receivable

$6.21M

+3100.5%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$0.00

-100.0%

Return on Assets

-42.15%

N/A

Return on Invested Capital

-56.99%

N/A

Free Cash Flow

-$19.92M

-98.9%

Operating Cash Flow

-$19.85M

-98.6%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

ALLOAllogene Therapeutics, Inc.

ALLOAllogene Therapeutics, Inc.$2.23+9.85%

CABACabaletta Bio, Inc.

CABACabaletta Bio, Inc.$3.10+6.53%

EDITEditas Medicine, Inc.

EDITEditas Medicine, Inc.$3.25+12.85%

NEONeoGenomics, Inc.

NEONeoGenomics, Inc.$16.66+4.75%

MASS908 Devices Inc.

MASS908 Devices Inc.$10.24+1.59%

BIOABioAge Labs Inc.

BIOABioAge Labs Inc.$10.75+2.77%

SENSSenseonics Holdings, Inc.

SENSSenseonics Holdings, Inc.$9.11+4.83%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

WBSWebster Financial

WBSWebster Financial$77.57-0.01%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$38.78+0.06%

MRNAModerna

MRNAModerna$174.38+1.77%

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF$47.05+0.06%

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF

SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF$120.74-0.06%

MSTRStrategy

MSTRStrategy$104.25+0.13%

ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF

ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF$15.88+0.10%

Questions About ACRS

What is the current price of Aclaris Therapeutics?

Aclaris Therapeutics is trading at $6.44 per share.

What is the 52-week range for Aclaris Therapeutics?

Over the past 52 weeks, Aclaris Therapeutics has traded between $1.74 and $6.52.

How much debt does Aclaris Therapeutics have?

As of the most recent reporting period, Aclaris Therapeutics reported total debt of $1.85M.

How much cash does Aclaris Therapeutics have on hand?

Aclaris Therapeutics reported $19.17M in cash and cash equivalents in its most recent financial results.

What is Aclaris Therapeutics’s dividend yield?

Aclaris Therapeutics does not currently have a dividend yield.

Aclaris Therapeutics(NASDAQ) ACRS

Aclaris Therapeutics Financials at a Glance

ACRS News

Why Aclaris Therapeutics Stock Soared Nearly 6% on Thursday

Why Aclaris Therapeutics Topped the Market on Tuesday

Why Aclaris Therapeutics Is Crashing Today

Why Aclaris Therapeutics Stock Skyrocketed More Than 200% Today

Here's Why Aclaris Therapeutics Stock Collapsed Today

Could These 2 Biotech Stocks Really Double Your Money?

Why Aclaris Therapeutics, Inc. Stock Is Down Today

The Best IPOs of 2015

ACRS: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Aclaris Therapeutics

The Pipeline at a Glance

Strategic Moves and Partnerships

How Aclaris Finds New Drugs

The Latest Financial Numbers

Bottom Line

ACRS Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Aclaris Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ACRS

What is the current price of Aclaris Therapeutics?

What is the 52-week range for Aclaris Therapeutics?

How much debt does Aclaris Therapeutics have?

How much cash does Aclaris Therapeutics have on hand?

What is Aclaris Therapeutics’s dividend yield?

Premium Investing Services